Hayashi, T., Shibata, M., Oe, S., Miyagawa, K., Honma, Y., & Harada, M. (2020). C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib. PLoS One.

Hayashi, Tsuguru, Michihiko Shibata, Shinji Oe, Koichiro Miyagawa, Yuichi Honma, and Masaru Harada. "C-reactive Protein Can Predict Dose Intensity, Time to Treatment Failure and Overall Survival in HCC Treated With Lenvatinib." PLoS One 2020.

Hayashi, Tsuguru, et al. "C-reactive Protein Can Predict Dose Intensity, Time to Treatment Failure and Overall Survival in HCC Treated With Lenvatinib." PLoS One 2020.